KCT0003745
Recruiting
未知
A randomized, open-label study to evaluate the efficacy and safety of plastic cannula compared with metal needle in incident hemodialysis patients
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Hallym University Medical Center
- Enrollment
- 60
- Status
- Recruiting
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Incident hemodialysis patients who newly created AVFs
- •\- Patients who can use low\-dose aspirin, as guidelines recommend
Exclusion Criteria
- •Patients with long\-standing use of steroid or immunosuppressive agents or pre\-existing skin diseases were all excluded.
- •Patients who cannot meet our Doppler criteria at needling point: adequate fistula size \= 0\.5 cm, blood flow \= 500 mL/min, depth from skin \< 1\.0 cm and presence of intact AVF configuration.
- •Patients who doesn't want
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
EXCITE-HT studyJPRN-jRCTs031220372Kario Kazuomi540
Completed
Not Applicable
Assessment of bone fracture healing efficacy of CL16019CTRI/2021/12/039006CLS Pvt Ltd
Recruiting
Phase 4
A randomised, open-label study to evaluate the efficacy and safety of maraviroc (MVC) as a switch for either nucleoside or nucleotide analogue reverse transcriptase inhibitors (N(t)RTI) or boosted protease inhibitors (PI/r) in HIV-1 infected individuals with stable, well-controlled plasma HIV-RNA while taking their first N(t)RTI + PI/r regimen of combination antiretroviral therapy (cART): MARCH studyHIVInflammatory and Immune System - Other inflammatory or immune system disordersInfection - Acquired immune deficiency syndrome (AIDS / HIV)ACTRN12611000816954niversity of New South Wales, Kirby Institute560
Active, not recruiting
Phase 1
Maraviroc switch studyEUCTR2011-002107-15-GBniversity of New South Wales380
Completed
Not Applicable
A randomized, open-label study evaluating the effects of food and dosing regimen on Q-122 pharmacokinetics in healthy female volunteersACTRN12617001542381Que Oncology12